Formoterol as relief medication in asthma: A worldwide safety and effectiveness trial

European Respiratory Journal

Volumn 22, Issue 5, 2003, Pages 787-794

  Pauwels, Romain A ^a   Sears, M R ^b   Campbell, M ^c   Villasante, C ^d   Huang, S ^e   Lindh, A ^f   Petermann, W ^g   Aubier, M ^h   Schwabe, G ⁱ   Bengtsson, T ⁱ  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^f Husläkarna i Österåker Health Centre   (Sweden)

^g Brüderkrankenhaus ^*  (Germany)

^h BICHAT HOSPITAL   (France)

ⁱ ASTRAZENECA R AND D   (Sweden)

Author keywords

Age; Asthma; Effectiveness; Formoterol; Safety; Salbutamol

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; INSPIRYL; SALBUTAMOL; SALMETEROL;

ADOLESCENT; ADULT; ALLERGIC RHINITIS; ANGINA PECTORIS; ANXIETY DISORDER; APPENDICITIS; ARTICLE; ASTHMA; BACKACHE; BRONCHITIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEART FAILURE; HUMAN; INFLUENZA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; TREMOR; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; AGED; AGED, 80 AND OVER; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; CHILD; CHILD, PRESCHOOL; ETHANOLAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 10744222040     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00055803     Document Type: Article

References (21)

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. National Institutes of Health. National Heart, Lung and Blood Institute, Publication 95-3659, 1995; 1-176.
2. British Thoracic Society. The British guidelines on asthma management. Thorax 1997; 52: Suppl. 1, 1-21.
3. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000; 16: 802-807.
4. Holgate ST. Therapeutic options for persistent asthma. JAMA 2001; 285: 2637-2639.
5. Derom EY, Pauwels RA. Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic. Thorax 1992; 47: 30-33.
6. Ringdal N, Derom E, Wåhlin-Boll E, Pauwels R. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler. Respir Med 1998; 92: 1017-1021.
7. Pauwels RA, Löfdahl C-G, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-1411.
8. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164: 1392-1397.
9. Tattersfield AE, Löfdahl CG, Postma DS, et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001; 357: 257-261.
10. Fraser PM, Speizer FE, Waters SD, Doll R, Mann NM. The circumstances preceding death from asthma in young people in 1968 to 1969. Br J Dis Chest 1971; 65: 71-84.
11. McIvor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158: 924-930.
12. Seberova E, Andersson A. Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med 2000; 94: 607-611.
13. Rosenborg J, Bengtsson T, Larsson P, Blomgren A, Persson G, Lötvall J. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics. Eur J Clin Pharmacol 2000; 56: 363-370.
14. Rosenborg J, Larsson P, Rott Z, Böcskei C, Poczi M, Juhász G. Relative therapeutic index between inhaled formoterol and salbutamol in asthma patients. Respir Med 2002; 96: 412-417.
15. Chapman KR, Friberg K, Balter MS, et al. Albuterol via Turbuhaler versus albuterol via pressurized metered-dose inhaler in asthma. Ann Allergy Asthma Immunol 1997; 78: 59-63.
16. Global Initiative for Asthma. Pocket guide for asthma management and prevention. National Institutes of Health. National Heart, Lung and Blood Institute, Publication 96-3659B, 1998; 1-29.
17. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391-1396.
18. Verberne AA, Frost C, Roorda RJ, van der Laag H, Kerrebijn KF. One-year treatment with salmeterol compared with beclomethasone in children with asthma. Am J Respir Crit Care Med 1997; 156: 688-695.
19. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320: 1368-1373.
20. Lemanske RF, Sorkness CA, Mauger EA, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol - A randomized controlled trial. JAMA 2001; 285: 2594-2603.
21. van der Molen T, Postma DS, Turner MO, et al. Effects of the long-acting beta-agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. Thorax 1997; 52: 535-539.